For the fifth year, Pharma Intelligence has analyzed the types of alliances, the scope of dealmaking activity, and the myriad of opportunities that continue to drive drug development in the biopharma industry. In their new white paper, Biopharma Partnering and Financing Trends, H1 2020, we learn the impact COVID-19 has had on the industry and how the first half of 2020 compares with the first half of 2019.
Financial value of the deals made
Reasons why deal volumes changed from one quarter to another
Highest partnership therapy areas
Impact COVID-10 had on partnership activity
The effect announced milestones had on deals